HALO compared with EVR: revenue, margins and what each company keeps, and the suppliers and customers both name

HALOHalozyme Therapeutics, Inc.

Mkt capRevenueRevenue

EVREvercore Inc.

Mkt capRevenueRevenue

Compare

HALOHalozyme Therapeutics, Inc.

EVREvercore Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

HALO1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±6.0%▲+20.24%×3.37

EVR2 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 28 '26±8.1%▲+12.51%×1.54

Q2 FY26—▼−10.51%—

= impliedHALO realized, solidEVR realized, hatchedOne scale, both sides: full bar = 21%× = |realized| ÷ impliedSource: market data

HALOHalozyme Therapeutics, Inc.

130.89▼−0.22%· post 130.16

Mkt cap$14.9BRevenue$481MQ2 FY26Revenue$1.4BFY25

EVREvercore Inc.

290.34▼−2.44%· post 290.32

ClosedOct 30 '26

Mkt cap$11.2BRevenue$2.9BQ2 FY26Revenue$11.5BFY25

Compare

ClosedOct 30 '26

HALOHalozyme Therapeutics, Inc.

EVREvercore Inc.

130.89▼−0.22%post 130.16

Price

290.34▼−2.44%post 290.32

$14.9B

Mkt cap

$11.2B

Q2 FY26$481M

Revenue

$2.9BQ2 FY26

FY25$1.4B

Revenue

$11.5BFY25

HALO130.89▼−0.22%vsEVR290.34▼−2.44%ClosedOct 30 '26